P Azzopardi1, C M Bennett, S M Graham, T Duke. 1. Melbourne School of Population Health, University of Melbourne, Department of Paediatrics, Royal Children's Hospital, Melbourne, Victoria, Australia. peter.azzopardi@rch.org.au
Abstract
OBJECTIVE: To describe the characteristics and risk of bacille Calmette-Guérin (BCG) vaccine related disease in human immunodeficiency virus (HIV) infected infants. METHODS: Systematic literature review of articles published from 1950 to April 2009 in the English language. We identified all microbiologically confirmed cases of disseminated BCG disease in vertically HIV-infected children reported in the literature. RESULTS: Sixteen observational studies and 11 case reports/series were included. Observational studies suffered from high rates of loss to follow-up and death. Loco-regional BCG disease was reported in both HIV-infected and non-infected children. Disseminated BCG disease was reported only in children with immunodeficiency and only in studies employing sophisticated laboratory techniques. Sixty-nine cases of disseminated BCG were identified in the literature: 47 cases were reported in six observational studies, the majority (41/47) from the Western Cape of South Africa. A Brazilian cohort study reported no cases of disseminated BCG amongst 66 HIV-infected children observed over a 7-year period. A recent South African surveillance study reported 32 cases of disseminated BCG over a 3-year period, estimating the risk of disseminated BCG to be 992 per 100,000 vaccinations in HIV-infected children. Few cases of severe disseminated TB were reported in the cohort studies among HIV-infected children vaccinated with BCG. CONCLUSION: Data on the risk of BCG vaccination in HIV-infected children are limited. Targeted surveillance for BCG complications employing sophisticated diagnostic techniques is required to inform vaccination policy.
OBJECTIVE: To describe the characteristics and risk of bacille Calmette-Guérin (BCG) vaccine related disease in human immunodeficiency virus (HIV) infectedinfants. METHODS: Systematic literature review of articles published from 1950 to April 2009 in the English language. We identified all microbiologically confirmed cases of disseminated BCG disease in vertically HIV-infectedchildren reported in the literature. RESULTS: Sixteen observational studies and 11 case reports/series were included. Observational studies suffered from high rates of loss to follow-up and death. Loco-regional BCG disease was reported in both HIV-infected and non-infected children. Disseminated BCG disease was reported only in children with immunodeficiency and only in studies employing sophisticated laboratory techniques. Sixty-nine cases of disseminated BCG were identified in the literature: 47 cases were reported in six observational studies, the majority (41/47) from the Western Cape of South Africa. A Brazilian cohort study reported no cases of disseminated BCG amongst 66 HIV-infectedchildren observed over a 7-year period. A recent South African surveillance study reported 32 cases of disseminated BCG over a 3-year period, estimating the risk of disseminated BCG to be 992 per 100,000 vaccinations in HIV-infectedchildren. Few cases of severe disseminated TB were reported in the cohort studies among HIV-infectedchildren vaccinated with BCG. CONCLUSION: Data on the risk of BCG vaccination in HIV-infectedchildren are limited. Targeted surveillance for BCG complications employing sophisticated diagnostic techniques is required to inform vaccination policy.
Authors: H Rabie; A Violari; T Duong; S A Madhi; D Josipovic; S Innes; E Dobbels; E Lazarus; R Panchia; A G Babiker; D M Gibb; M F Cotton Journal: Int J Tuberc Lung Dis Date: 2011-09 Impact factor: 2.373
Authors: Edwin J Asturias; Melinda Wharton; Robert Pless; Noni E MacDonald; Robert T Chen; Nicholas Andrews; David Salisbury; Alexander N Dodoo; Kenneth Hartigan-Go; Patrick L F Zuber Journal: Vaccine Date: 2016-05-16 Impact factor: 3.641
Authors: Marcela Parra; Steven C Derrick; Amy Yang; Jinhua Tian; Kristopher Kolibab; Miranda Oakley; Liyanage P Perera; William R Jacobs; Sanjai Kumar; Sheldon L Morris Journal: PLoS One Date: 2011-12-19 Impact factor: 3.240